A reason to celebrate: multimodal treatments and recent improvements in the long-term outcomes of patients with chronic thromboembolic pulmonary hypertension
- PMID: 40659467
- DOI: 10.1183/13993003.00562-2025
A reason to celebrate: multimodal treatments and recent improvements in the long-term outcomes of patients with chronic thromboembolic pulmonary hypertension
Conflict of interest statement
Conflict of interest: I.M. Lang has relationships with drug companies including AOP-Health, Actelion-Janssen, MSD, United Therapeutics, Pulnovo, Medtronic, NovoNordisk, Amarin, Daiichi and Sanofi. In addition to being investigator in trials involving these companies, relationships include consultancy service, research grants, and membership of scientific advisory boards.
Comment on
-
Survival trends in patients with chronic thromboembolic pulmonary hypertension: an observational study.Eur Respir J. 2025 Jul 14;66(1):2402268. doi: 10.1183/13993003.02268-2024. Print 2025 Jul. Eur Respir J. 2025. PMID: 40049724 Free PMC article.
Publication types
LinkOut - more resources
Full Text Sources